2021
DOI: 10.1080/20009666.2020.1867295
|View full text |Cite
|
Sign up to set email alerts
|

The use of direct acting oral anticoagulants in patients with COVID-19 infection

Abstract: The use of direct-acting oral anticoagulants (DOACs) has increased rapidly in the last decade; becoming the mainstay for both the prophylaxis and the treatment of venous thromboembolism in various situations including non-valvular atrial fibrillation, joint replacement surgeries and acute DVT/PE, etc. In the present times, DOACs are possibly one of the most widely prescribed medications in the developed world. The worldwide epidemic caused by COVID-19 caused significant changes in the practice of medicine worl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
4
0
2

Year Published

2021
2021
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 14 publications
0
4
0
2
Order By: Relevance
“…Nonetheless, the published data for DOACs in the field of COVID-19 is conflicting. In the context of hospitalization, many of the COVID-19 patients with prior DOAC therapy will be switched to heparins because they are expected to receive medications interacting with DOACs, or have coagulation system and homeostasis disorders [ 52 , 53 ]. For this reason, it is necessary to act before hospitalization in these especially vulnerable patients.…”
Section: Discussionmentioning
confidence: 99%
“…Nonetheless, the published data for DOACs in the field of COVID-19 is conflicting. In the context of hospitalization, many of the COVID-19 patients with prior DOAC therapy will be switched to heparins because they are expected to receive medications interacting with DOACs, or have coagulation system and homeostasis disorders [ 52 , 53 ]. For this reason, it is necessary to act before hospitalization in these especially vulnerable patients.…”
Section: Discussionmentioning
confidence: 99%
“…Currently, there are no specific treatments for COVID-19, and the globally applied therapeutic strategies are based on repurposing the available drugs as antiviral agents (e.g., ivermectin and niclosamide) [ 2 , 3 , 4 , 5 , 6 ] or controlling the host immune response by using immunomodulatory agents and corticosteroids [ 7 , 8 ]. Moreover, anticoagulants were reported to be used in patients with severe COVID-19 illness [ 9 , 10 ]. Besides, antibiotics have been used extensively as a protective measure against secondary bacterial co-infection or superinfections [ 11 , 12 ] ( Figure 1 ).…”
Section: Introductionmentioning
confidence: 99%
“…For COVID-19 patients without suspected or confirmed VTE, the American Society of Hematology 2021 recommended prophylactic anticoagulation over intermediate or therapeutic-intensity anticoagulation [ 12 ]. Contraindication in renal and hepatic impairment [ 59 ] and the possibility of several drug–drug interactions, particularly with the antiviral agents, need to be considered while initiating a pharmacological thromboprophylaxis [ 60 , 61 , 62 ].…”
Section: Thromboprophylaxismentioning
confidence: 99%